<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295538</url>
  </required_header>
  <id_info>
    <org_study_id>M16-077</org_study_id>
    <secondary_id>2019-003752-36</secondary_id>
    <nct_id>NCT04295538</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)</brief_title>
  <acronym>ELASCI</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment&#xD;
      and sudden disability. Approximately 25,000 people experience cervical SCI in the United&#xD;
      States, Europe, and Japan every year. The purpose of this study is to see if elezanumab is&#xD;
      safe and assess change in Upper Extremity Motor Score (UEMS) in participants with acute&#xD;
      traumatic cervical SCI.&#xD;
&#xD;
      Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is&#xD;
      a monoclonal antibody, that binds to an inhibitor of neuronal regeneration and neutralizes&#xD;
      the inhibitor, thus potentially promoting neuroregeneration. This study is &quot;double-blinded&quot;,&#xD;
      which means that neither trial participants nor the study doctors will know who will be given&#xD;
      which study drug. Study doctors put the participants in 1 of 2 groups, called treatment arms.&#xD;
      Each group receives a different treatment. There is a 1 in 3 chance that participants will be&#xD;
      assigned to placebo. Participants 18-70 years of age with a SCI will be enrolled.&#xD;
      Approximately 54 participants will be enrolled in the study in approximately 36 sites&#xD;
      worldwide.&#xD;
&#xD;
      Participants will receive intravenous (IV) doses of elezanumab or placebo within 24 hours of&#xD;
      injury and every 4 weeks thereafter through Week 48 for a total of 13 doses.&#xD;
&#xD;
      There may be a higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the course of the study at a&#xD;
      hospital or clinic. The effect of the treatment will be checked by medical assessments, blood&#xD;
      tests, checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2020</start_date>
  <completion_date type="Anticipated">May 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upper Extremity Motor Score (UEMS)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The UEMS is a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) that grades function of 5 key muscles in the upper limbs on a scale of 0 to 5 on each side from total paralysis to active full range of movement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Spinal Cord Independence Measures (SCIM III) Self-Care Score</measure>
    <time_frame>Week 0 through Week 52</time_frame>
    <description>The SCIM III self-care score addresses four areas of self-care management: feeding, grooming, bathing, and dressing. It has a total of 4 questions. Scores range from 0-20 where a score of 0 defines total dependence and 20 is indicative of complete independence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Upper Extremity Motor Score (UEMS) From Baseline</measure>
    <time_frame>Week 0 through Week 52</time_frame>
    <description>The UEMS is a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) that grades function of 5 key muscles in the upper limbs on a scale of 0 to 5 on each side from total paralysis to active full range of movement, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Spinal Cord Injury (SCI)</condition>
  <arm_group>
    <arm_group_label>Elezanumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive elezanumab dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for elezanumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elezanumab</intervention_name>
    <description>Solution for infusion; Intravenous (IV)</description>
    <arm_group_label>Elezanumab</arm_group_label>
    <other_name>ABT-555</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for infusion; Intravenous (IV)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute traumatic cervical SCI, neurological level of injury of C4, C5, C6, or C7 with&#xD;
             no damage to cord in thoracic (T2 and beyond) and lumbar regions that, in the&#xD;
             investigator's opinion, would significantly limit recovery.&#xD;
&#xD;
          -  Maximum screening UEMS of 32.&#xD;
&#xD;
          -  American Spinal Injury Association Impairment Scale (AIS) grade A or B at Screening.&#xD;
&#xD;
          -  Able to initiate study drug administration within 24 hours of injury.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of complete spinal cord transection.&#xD;
&#xD;
          -  Significant concomitant head injury with a clinically significant abnormality on a&#xD;
             head computed tomography (CT).&#xD;
&#xD;
          -  One or more upper extremity muscle groups untestable (e.g., immobilized or restricted&#xD;
             by a cast) during the screening ISNCSCI examination.&#xD;
&#xD;
          -  Known history prior to randomization of clinically significant medical or surgical&#xD;
             conditions (other than current acute SCI) or any other reason, including any physical,&#xD;
             psychological, or psychiatric condition that in the opinion of the Investigator would&#xD;
             compromise the safety or interfere with the participant's participation in this study,&#xD;
             or would make the participant an unsuitable candidate to receive study drug, or would&#xD;
             put the participant at risk by participating in the study, including history of or&#xD;
             abnormal screening lab or imaging results that, in the opinion of the investigator,&#xD;
             are indicative of any irreparable cardiac, endocrinologic, hematologic, hepatic,&#xD;
             immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal,&#xD;
             dermatologic, psychiatric, renal, neurologic, and/or other major disease that would&#xD;
             preclude administration of elezanumab.&#xD;
&#xD;
          -  Known receipt of any other investigational product within 30 days or 5 half-lives of&#xD;
             the drug (whichever is longer) prior to the first dose of study drug or is currently&#xD;
             enrolled in another clinical study.&#xD;
&#xD;
          -  Female who is pregnant, breastfeeding, or considering becoming pregnant during the&#xD;
             study or for within 39 weeks (5 half-lives) after the last dose of study drug.&#xD;
&#xD;
          -  The cause of the acute SCI is one of the following: from gunshot or penetrating/stab&#xD;
             wound; non-traumatic SCI, results of seizure, or known attempted suicide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Health-Neurological Surgery /ID# 224892</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-2307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shepherd Center, Inc /ID# 230370</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309-1426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine /ID# 218009</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Institue of Chicago /ID# 216327</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville /ID# 215948</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center /ID# 225410</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111-1552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital /ID# 216342</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine /ID# 218371</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118-2515</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center /ID# 218149</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regents of the University of Michigan /ID# 215890</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-1276</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 215325</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack Univ Med Ctr /ID# 215754</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center /ID# 218162</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753-4859</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey School of Medicine /ID# 216212</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center /ID# 216888</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University /ID# 227371</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania /ID# 218662</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital /ID# 215460</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health /ID# 218117</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital /ID# 218302</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center Main Hospital /ID# 217481</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospitals /ID# 217344</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin /ID# 215610</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 216953</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Foothills Medical Centre /ID# 214790</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>QEII - Health Sciences Centre /ID# 215249</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Civic Campus /ID# 215270</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital /ID# 215214</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Nord-de-l'ile-de-Montréal_Hopital du Sacré-Coeur de Montréal /ID# 215210</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHO Nagoya Medical Center /ID# 239617</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Funabashi Municipal Medical Center /ID# 225599</name>
      <address>
        <city>Funabashi-shi</city>
        <state>Chiba</state>
        <zip>273-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Murayama Medical Center /ID# 223492</name>
      <address>
        <city>Musashimurayama-shi</city>
        <state>Tokyo</state>
        <zip>2080011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japan Organization of Occupational Health and Safety Spinal Injuries Centre /ID# 224141</name>
      <address>
        <city>Iizuka-shi</city>
        <zip>820-8508</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital /ID# 238890</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruna - CHUAC /ID# 216384</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron /ID# 217794</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre /ID# 225354</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio /ID# 225692</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Paraplejicos /ID# 225508</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe /ID# 217797</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Cord Injury (SCI)</keyword>
  <keyword>Cervical Spinal Cord Injury</keyword>
  <keyword>Cervical SCI</keyword>
  <keyword>Elezanumab</keyword>
  <keyword>ABT-555</keyword>
  <keyword>Upper Extremity Motor Score (UEMS)</keyword>
  <keyword>Acute Traumatic Cervical Spinal Cord Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

